register

News & Trends - Pharmaceuticals

Will AbbVie’s life cycle extension strategies set Humira apart from the biosimilars?

Health Industry Hub | March 30, 2021 |
[Total: 1    Average: 4/5]

Pharma News: AbbVie Australia announced that a new formulation of HUMIRA will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 April 2021.

Two new Humira (adalimumab) biosimilars are also eligible for reimbursement from April 1st – HADLIMA (commercialised by MSD and manufactured by Korea’s Samsung Bioepis) and Fresenius Kabi’s IDACIO.

AbbVie’s life cycle extension strategies aim to set Humira apart from the biosimilars in the market.

The removal of citrate and other inactive ingredients from Humira, as well as the introduction of a new autoinjector pen and a reduced injection volume, are all part of AbbVie’s commitment to take patient feedback on board and innovate to support adherence to treatment.

The new autoinjector pen has also been designed to simplify the injection process and increase injection confidence. In a patient survey (N=476), more patients (65%) preferred the new, re-designed pen compared to the previous pen (35%).

Digital & Innovation - Health Industry Hub Digital Series

Dr Edward Giles, Consultant Paediatric Gastroenterologist at Monash Children’s Hospital, said this is welcome news for Australian patients who self-administer their treatment.

“For many of my young patients with Crohn’s Disease, Humira is keeping their disease under control, keeping them out of hospital and in school. Anything that makes the experience of taking their long-term medication easier will be welcomed by patients and their families,” said Dr Giles.

Chris Stemple, General Manager and Vice President of AbbVie Australia, said “We are proud that innovation and research has led to subsidised access to the Humira citrate-free formulation for eligible Australians with autoimmune diseases. Developing this formulation is part of our ongoing commitment to invest in continued development of our medicines to support patients and their adherence to treatment.”

MSD’s Biosimilar Business Unit Director, Michael Van Lathum, said “HADLIMA plays an important role in providing patients with treatment choice and this listing furthers our commitment to creating a sustainable PBS by using biosimilars to help reduce the cost of medicines for Australian taxpayers.”

Martin Monaghan, Country Manager, Australia and New Zealand said “It is an exciting moment and an important milestone for us as a company to launch our first biosimilar product in Australia. Biosimilars are an important contributing factor to the sustainability of the PBS and in line with our philosophy of ‘caring for life’ the launch of IDACIO provides a new adalimumab choice for patients suffering with autoimmune disease.”

Humira, with $300 million in sales in 2020, is currently indicated for 10 autoimmune conditions across rheumatology, dermatology, gastroenterology and ophthalmology in Australia.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]

More


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]

More


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]

More